GlaxoSmithKline Pharmaceuticals Limited
₹2,567.90▲ +43.20 (+1.71%)
GLAXO·NSE·Healthcare
Market Cap
43456.04 Cr
PE Ratio
47.10
Volume
61,686
Day High - Low
2573.20 - 2518.40
52W High-Low
3120.70 - 2088.10
₹2,567.90▲ +43.20 (+1.71%)
Market Cap43456.04 Cr
PE Ratio47.10
Volume61,686
Day High - Low2573.20 - 2518.40
52W High-Low3120.70 - 2088.10
GlaxoSmithKline Pharmaceuticals Limited (GLAXO): company summary
The company's annual revenue rose 1.9% to ₹3,822 crore, while annual net profit increased 11.6% to ₹1,036 crore.
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is a mid-cap Healthcare company valued at ₹43,456 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- GlaxoSmithKline Pharmaceuticals Limited last traded at ₹2,567.9, modestly up 1.71% on the day.
- Recent developments
- On 2026-05-29, the company announced a dividend of ₹57.00 per share, effective from that date. Promoter holding remained at 75.00% as of 2026-06-30, with foreign institutional holding increasing by 0.17 percentage points and domestic institutional holding rising by 0.12 percentage points in the quarter.
- Financial performance
- The company's annual revenue rose 1.9% to ₹3,822 crore, while annual net profit increased 11.6% to ₹1,036 crore. In the latest quarter, revenue grew 16.6% year-on-year to ₹938 crore, and net profit rose 15.7% to ₹237 crore, reflecting stronger performance compared to the same quarter a year earlier.
- Valuation multiples
- The stock trades at 47.1 times earnings, a premium to the Healthcare median of 32.0, 21.22 times book value. It yields 2.0%.
- Things to watch
- The stock is 18.6% below its 52-week high, and the company's market cap is ₹43,026 crore, which is mid-cap. The latest quarter net profit margin is 27.1%, up from 24.8% the prior year, but the company remains almost debt-free with a debt-to-equity ratio of 0.00.
- Where it stands
- The company has shown consistent growth in both revenue and net profit over the past five years, with a 23.7% CAGR in profit. The latest quarter saw a 15.7% increase in net profit compared to the same quarter a year earlier. The stock is currently 18.6% below its 52-week high.
Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
6.3/10
Fair
Fair Value
Sign in to see
ROE
45.69%
Strong
P/E
47.10x
Expensive
Debt / Equity
0.00
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
NIFTY 500NIFTY MIDCAP 150
Day₹2518
₹2573
52W₹2088
₹3121
DocStoX take
Supported by risk (9.3) and quality (9.2), but held back by valuation (0.0). Risk looks strong at 9.3, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence6.3
/10
Fair
Quality
Excellent
ROE 45.7%
Valuation
Expensive
P/E 47.1×
Growth
Steady
Revenue +3.6% 5Y CAGR
Risk
Low risk
D/E 0.00
Momentum
Soft
46% of 52-week range
At a glance
Market Cap
₹43,456 Cr
52W High / Low
₹3121 / ₹2088
Dividend Yield
2.01%
Promoter Holding
75.00%
EPS (TTM)
₹54.52
Book Value
₹133.84
Key highlights
- Capital works hard — ROCE 62%
- Strong returns on equity (46%)
- Low leverage — D/E 0.00
- Valuation is weak (0.0/10)
- Revenue barely growing (4% a year)
4 Positives2 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore GlaxoSmithKline Pharmaceuticals Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
GlaxoSmithKline Pharmaceuticals Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare GlaxoSmithKline Pharmaceuticals Limited with peers
GlaxoSmithKline Pharmaceuticals Limited vs Sun Pharmaceutical Industries LimitedGlaxoSmithKline Pharmaceuticals Limited vs Divi's Laboratories LimitedGlaxoSmithKline Pharmaceuticals Limited vs Torrent Pharmaceuticals LimitedGlaxoSmithKline Pharmaceuticals Limited vs Apollo Hospitals Enterprise LimitedGlaxoSmithKline Pharmaceuticals Limited vs Zydus Lifesciences LimitedGlaxoSmithKline Pharmaceuticals Limited vs Laurus Labs Limited
Related tools & concepts
Value GlaxoSmithKline Pharmaceuticals Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing